Alicia Del Toro-Arreola

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3350793/publications.pdf

Version: 2024-02-01

1040056 1372567 10 440 9 10 citations g-index h-index papers 10 10 10 950 docs citations times ranked citing authors all docs

#	Article	lF	CITATIONS
1	Association of the genetic variants (â€ 7 94 CATT5â€8 and â€173 GÂ>ÂC) of macrophage migration inhibitory factor (MIF) with higher soluble levels of MIF and TNFα in women with breast cancer. Journal of Clinical Laboratory Analysis, 2020, 34, e23209.	2.1	7
2	Circulating soluble levels of MIF in women with breast cancer in the molecular subtypes: relationship with Th17 cytokine profile. Clinical and Experimental Medicine, 2019, 19, 385-391.	3.6	22
3	Preparation of PLGA/Rose Bengal colloidal particles by double emulsion and layer-by-layer for breast cancer treatment. Journal of Colloid and Interface Science, 2018, 518, 122-129.	9.4	20
4	Characterization of B7H6, an endogenous ligand for the NK cell activating receptor NKp30, reveals the identity of two different soluble isoforms during normal human pregnancy. Immunobiology, 2018, 223, 57-63.	1.9	16
5	The role of endothelial cells on islet function and revascularization after islet transplantation. Organogenesis, 2016, 12, 28-32.	1.2	22
6	MHC class I-related chain A and B ligands are differentially expressed in human cervical cancer cell lines. Cancer Cell International, $2011,11,15.$	4.1	15
7	Low NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions. BMC Cancer, 2009, 9, 186.	2.6	164
8	Protease-activated receptor-2 (PAR-2) in cervical cancer proliferation. Gynecologic Oncology, 2008, 108, 19-26.	1.4	26
9	Augmented serum level of major histocompatibility complex class I-related chain A (MICA) protein and reduced NKG2D expression on NK and T cells in patients with cervical cancer and precursor lesions. BMC Cancer, 2008, 8, 16.	2.6	70
10	Effect of d-limonene on immune response in BALB/c mice with lymphoma. International Immunopharmacology, 2005, 5, 829-838.	3.8	78